<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39385581</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-0258</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>10</Day></PubDate></JournalIssue><Title>Statistics in medicine</Title><ISOAbbreviation>Stat Med</ISOAbbreviation></Journal><ArticleTitle>Does Remdesivir Lower COVID-19 Mortality? A Subgroup Analysis of Hospitalized Adults Receiving Supplemental Oxygen.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/sim.10241</ELocationID><Abstract><AbstractText>The first Adaptive COVID-19 Treatment Trial (ACTT-1) showed that remdesivir improved COVID-19 recovery time compared with placebo in hospitalized adults. The secondary outcome of mortality was almost significant overall (p = 0.07) and highly significant for people receiving supplemental oxygen at enrollment (p = 0.002), suggesting a mortality benefit concentrated in this group. We explore analysis methods that are helpful when a single subgroup benefits from treatment and apply them to ACTT-1, using baseline oxygen use to define subgroups. We consider two questions: (1) is the remdesivir effect for people receiving supplemental oxygen real, and (2) does this effect differ from the overall effect? For Question 1, we apply a Bonferroni adjustment to subgroup-specific hypothesis tests and the Westfall and Young permutation test, which is valid when small cell counts preclude normally distributed test statistics (a frequently unexamined condition in subgroup analyses). For Question 2, we introduce Q<sub>max</sub>, the largest standardized difference between subgroup-specific effects and the overall effect. Q<sub>max</sub> simultaneously tests whether any subgroup effect differs from the overall effect and identifies the subgroup benefitting most. We demonstrate that Q<sub>max</sub> strongly controls the familywise error rate (FWER) when test statistics are normally distributed with no mean-variance relationship. We compare Q<sub>max</sub> to a related permutation test, SEAMOS, which was previously proposed but not extensively applied or tested. We show that SEAMOS can have inflated Type 1 error under the global null when control arm event rates differ between subgroups. Our results support a mortality benefit from remdesivir in people receiving supplemental oxygen.</AbstractText><CopyrightInformation>Published 2024. This article is a U.S. Government work and is in the public domain in the USA. Statistics in Medicine published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Potter</LastName><ForeName>Gail E</ForeName><Initials>GE</Initials><Identifier Source="ORCID">0000-0001-6667-6992</Identifier><AffiliationInfo><Affiliation>Clinical Trials Research Section, Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proschan</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0002-9161-3739</Identifier><AffiliationInfo><Affiliation>Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stat Med</MedlineTA><NlmUniqueID>8215016</NlmUniqueID><ISSNLinking>0277-6715</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Q</Keyword><Keyword MajorTopicYN="N">Qmax</Keyword><Keyword MajorTopicYN="N">SEAMOS</Keyword><Keyword MajorTopicYN="N">heterogeneity</Keyword><Keyword MajorTopicYN="N">permutation</Keyword><Keyword MajorTopicYN="N">subgroup</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>3</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39385581</ArticleId><ArticleId IdType="doi">10.1002/sim.10241</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>J. H. Beigel, K. M. Tomashek, L. E. Dodd, et al., “Remdesivir for the Treatment of COVID‐19,” New England Journal of Medicine 383, no. 19 (2020): 1813–1826.</Citation></Reference><Reference><Citation>J. M. Grouin, M. Coste, and J. Lewis, “Subgroup Analyses in Randomized Clinical Trials: Statistical and Regulatory Issues,” Journal of Biopharmaceutical Statistics 15, no. 5 (2005): 869–882.</Citation></Reference><Reference><Citation>C. Mayer, I. Lipkovich, and A. Dmitrienko, “Survey Results on Industry Practices and Challenges in Subgroup Analysis in Clinical Trials,” Statistics in Biopharmaceutical Research 7, no. 4 (2015): 272–282.</Citation></Reference><Reference><Citation>A. Dmitrienko, B. Millen, and I. Lipkovich, “Multiplicity Considerations in Subgroup Analysis,” Statistics in Medicine 36, no. 28 (2017): 4446–4454.</Citation></Reference><Reference><Citation>I. Lipkovich, A. Dmitrienko, and B. D'Agostino, Sr., “Tutorial in Biostatistics: Data‐Driven Subgroup Identification and Analysis in Clinical Trials,” Statistics in Medicine 36, no. 1 (2017): 136–196.</Citation></Reference><Reference><Citation>W. Y. Loh, L. Cao, and P. Zhou, “Subgroup Identification for Precision Medicine: A Comparative Review of 13 Methods,” Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery 9, no. 5 (2019): e1326.</Citation></Reference><Reference><Citation>European Medicines Agency, Committee for Medicinal Products for Human Use, “Guideline on the Investigation of Subgroups in Confirmatory Clinical Trials” (2019), https://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐investigation‐subgroups‐confirmatory‐clinical‐trials_en.pdf.</Citation></Reference><Reference><Citation>M. Alosh, K. Fritsch, M. Huque, et al., “Statistical Considerations on Subgroup Analysis in Clinical Trials,” Statistics in Biopharmaceutical Research 7, no. 4 (2015): 286–303.</Citation></Reference><Reference><Citation>A. Dmitrienko and R. D'Agostino, Sr., “Traditional Multiplicity Adjustment Methods in Clinical Trials,” Statistics in Medicine 32, no. 29 (2013): 5172–5218.</Citation></Reference><Reference><Citation>R. Marcus, P. Eric, and K. R. Gabriel, “On Closed Testing Procedures With Special Reference to Ordered Analysis of Variance,” Biometrika 63, no. 3 (1976): 655–660.</Citation></Reference><Reference><Citation>S. K. Sarkar, On the Simes Inequality and Its Generalization (Beachwood, Ohio: Institute of Mathematical Statistics, 2008), 231–242.</Citation></Reference><Reference><Citation>P. H. Westfall and S. S. Young, “P Value Adjustments for Multiple Tests in Multivariate Binomial Models,” Journal of the American Statistical Association 84, no. 407 (1989): 780–786.</Citation></Reference><Reference><Citation>P. H. Westfall and J. F. Troendle, “Multiple Testing With Minimal Assumptions,” Biometrical Journal: Journal of Mathematical Methods in Biosciences 50, no. 5 (2008): 745–755.</Citation></Reference><Reference><Citation>A. Dane, A. Spencer, G. Rosenkranz, I. Lipkovich, T. Parke, and Subgroup Analysis oPWG, “Subgroup Analysis and Interpretation for Phase 3 Confirmatory Trials: White Paper of the EFSPI/PSI Working Group on Subgroup Analysis,” Pharmaceutical Statistics 18, no. 2 (2019): 126–139.</Citation></Reference><Reference><Citation>D. J. Shahar, “Minimizing the Variance of a Weighted Average,” Open Journal of Statistics 7, no. 2 (2017): 216–224.</Citation></Reference><Reference><Citation>W. G. Cochran, “The Combination of Estimates From Different Experiments,” Biometrics 10, no. 1 (1954): 101–129.</Citation></Reference><Reference><Citation>P. H. Westfall and S. S. Young, Resampling‐Based Multiple Testing (New York, NY: Citeseer, 2002).</Citation></Reference><Reference><Citation>P. H. Westfall, S. S. Young, and S. P. Wright, “On Adjusting P‐Values for Multiplicity,” Biometrics 49, no. 3 (1993): 941–945.</Citation></Reference><Reference><Citation>A. P. Chokkalingam, J. Hayden, J. D. Goldman, et al., “Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID‐19 in the United States,” JAMA Network Open 5, no. 12 (2022): e2244505.</Citation></Reference><Reference><Citation>G. A. Diaz, A. B. Christensen, T. Pusch, et al., “Remdesivir and Mortality in Patients With Coronavirus Disease 2019,” Clinical Infectious Diseases 74, no. 10 (2021): 1812–1820.</Citation></Reference><Reference><Citation>A. Amstutz, B. Speich, F. Mentré, et al., “Effects of Remdesivir in Patients Hospitalised With COVID‐19: A Systematic Review and Individual Patient Data Meta‐Analysis of Randomised Controlled Trials,” Lancet Respiratory Medicine 11, no. 5 (2023): 453–464.</Citation></Reference><Reference><Citation>R. Beckerman, A. Gori, S. Jeyakumar, et al., “Remdesivir for the Treatment of Patients Hospitalized With COVID‐19 Receiving Supplemental Oxygen: A Targeted Literature Review and Meta‐Analysis,” Scientific Reports 12, no. 1 (2022): 9622.</Citation></Reference><Reference><Citation>WHO Solidarity Trial Consortium, “Remdesivir and Three Other Drugs for Hospitalised Patients With COVID‐19: Final Results of the WHO Solidarity Randomised Trial and Updated Meta‐Analyses,” Lancet 399, no. 10339 (2022): 1941–1953.</Citation></Reference><Reference><Citation>C. Huang, T. L. Lu, and L. Lin, “Remdesivir Treatment Lacks the Effect on Mortality Reduction in Hospitalized Adult COVID‐19 Patients Who Required High‐Flow Supplemental Oxygen or Invasive Mechanical Ventilation,” Medicina 59, no. 6 (2023): 1027.</Citation></Reference><Reference><Citation>T. C. Lee, S. Murthy, O. Del Corpo, et al., “Remdesivir for the Treatment of COVID‐19: A Systematic Review and Meta‐Analysis,” Clinical Microbiology and Infection 28, no. 9 (2022): 1203–1210.</Citation></Reference><Reference><Citation>D. C. Hoaglin, “Misunderstandings About Q and “Cochran's Q Test” in Meta‐Analysis,” Statistics in Medicine 35, no. 4 (2016): 485–495.</Citation></Reference><Reference><Citation>E. Kulinskaya and M. B. Dollinger, “Commentary on “Misunderstandings About Q and Cochran's Q Test” in Meta Analysis,” Statistics in Medicine 35, no. 4 (2016): 501–502.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>